Covid-19 living Data

Pharmacologic treatments for covid-19 patients

Methods

Protocol amendment:

As of December 14, 2022, the COVID-NMA revised its protocol and stopped including pharmacological interventions trials. The analysis presented in this page includes trials identified and included up to December 14, 2022. Ofnote, different last search date are considered by category. We provide the updated results up to last search defined next to each comparison including all identified reports through our search strategy up to this date.

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

Summary of Main Results

Summary of the evidence for pharmacological treatment of hospitalized COVID-19 patients identified up to October 17, 2022 is available below.

For earlier editions of the summary of main results, click here

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Display new or updated analyses

Display all results

Your research: Tocilizumab

Access the forest plots for the 19 treatment comparisons .

Comparisons evaluating antivirals and immunomodulators with last search date December 14, 2022.

Anti-virals (5 comparisons) update new

Kinase inhibitor (2 comparisons) update new

Corticosteroids (3 comparisons) update new

Monoclonal antibodies (18 comparisons) update new

Anakinra vs Tocilizumab - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022)

Anakinra vs Siltuximab - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022)

Anakinra vs Standard care/Placebo - 8 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022)

Anakinra + Tocilizumab vs Standard care - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022)

Baricitinib vs Tocilizumab - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022)

Favipiravir vs Favipiravir+Tocilizumab - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022.)

Favipiravir vs Tocilizumab - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022.)

Methylprednisolone vs Methylprednisolone +Tocilizumab - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022)

Sarilumab vs Standard care/Placebo - 11 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022.)

Siltuximab vs Standard care - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022)

Tocilizumab vs Siltuximab - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022)

Tocilizumab vs Standard care/Placebo - 21 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022.)

Tocilizumab vs Favipiravir+Tocilizumab - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022.)

Tocilizumab vs Dexamethasone - 2 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022)

Tocilizumab + Dexamethasone vs Dexamethasone - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022)

Tocilizumab + HCQ/AZM vs HCQ/AZM - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022)

Tocilizumab + Remdesivir vs Remdesivir - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022.)

Tocilizumab 4 mg/kg vs Tocilizumab 8 mg/kg - 1 RCTs (This comparison will not be updated. Last search date 14 Dec, 2022)

Comparisons with last search date 28 February 2022 or as stated next to each comparison.

Search studies

General characteristics of primary studies

Trial	Funding	Comparisons		Design	Participants	Sample size	Overall risk of bias Highest assessment	Full description
		Treatment 1	Treatment 2
NCT04678739 Mohiuddin Chowdhury ATM, Front pharmacol, 2022 Full text Commentary	Not reported/unclear	Tocilizumab + Remdesivir	Dexamethasone	RCT	Patients with confirmed COVID-19 (severe) admitted to 3 centers in Bangladesh	N=208	Some concerns Details	Full description
NCT05082714 Karampitsakos T, medRxiv, 2022 Full text Commentary Commentary	No specific funding	Baricitinib	Tocilizumab	RCT	Patients with confirmed COVID-19 (severe) admitted to a single center in Greece.	N=251	Some concerns Details	Full description
NCT04363736 MARIPOSA Kumar PN, Open Forum Infect Dis, 2021 Full text Commentary Commentary	Private	Tocilizumab 4 mg/kg	Tocilizumab 8 mg/kg	RCT	Patients with confirmed COVID-19 (mild-critical) admitted to 26 centers in the USA.	N=100	Some concerns Details	Full description
CTRI/2021/04/033263 Naik NB, Cureus, 2021 Full text Commentary Commentary	Public/non profit	Tocilizumab	Dexamethasone High Dose	RCT	Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in India	N=42	Some concerns Details	Full description
NCT04330638; EudraCT2020-001500-41 COV-AID Declercq J, Lancet Respir Med, 2021 Full text Commentary Commentary	Public/non profit	Anakinra Tocilizumab Siltuximab Anakinra Anakinra Tocilizumab Anakinra + Tocilizumab	Standard care Standard care Standard care Tocilizumab Siltuximab Siltuximab Standard care	RCT	Patients with confirmed COVID-19 (moderate-critical) admitted to 16 centers in Belgium.	N=342	Some concerns Details	Full description
NCT04412291, EudraCT 2020-001748-24 IMMCOVA IMMCOVA, Unpublished, 2021 Extracted from REACT meta-analysis: Full text	Public/non profit	Tocilizumab	Standard care	RCT	Patients with confirmed COVID-19 (moderate-severe) admitted to a multiple centerd in Sweden	N=49	Low Details	Full description
NCT04435717 COVITOZ-01 COVITOZ-01, Unpublished, 2021 Extracted from REACT meta-analysis: Full text	Public/non profit	Tocilizumab	Standard care	RCT	Patients with suspected or confirmed COVID-19 (mild-moderate-severe) admitted to a single center in Spain.	N=26	Low Details	Full description
NCT04577534 COVIDSTORM Broman N, Clin Microbiol Infect, 2022 Full text Commentary	No specific funding	Tocilizumab	Standard care	RCT	Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Finland.	N=88	Some concerns Details	Full description
NCT04409262 REMDACTA Rosas IO, Intensive Care Med, 2021 Full text Commentary	Private	Tocilizumab + Remdesivir	Remdesivir	RCT	Patients with confirmed COVID-19 (severe-critical) admitted to multiple centers in Spain, USA, Brazil and Russia.	N=649	Some concerns Details	Full description
NCT04377750 HMO-0224-20 HMO-0224-20, Unpublished, 2021 Extracted from REACT meta-analysis: Full text	Public/non profit	Tocilizumab	Placebo	RCT	Patients with confirmed COVID-19 (severe-critical) admitted to multiple centers in Israel.	N=54	High Details	Full description
NCT04332094, EudraCT 2020-001442-19 TOCOVID TOCOVID, Unpublished, 2021 Extracted from REACT meta-analysis: Full text	Public/non profit	Tocilizumab +HCQ/AZM	Hydroxychloroquine +Azithromycin	RCT	Patients with confirmed COVID-19(mild-moderate) admitted to multiple centers in Spain.	N=270	Low Details	Full description
NCT04479358 COVIDOSE-2 COVIDOSE-2, Unpublished, 2021 Extracted from REACT meta-analysis: Full text	Public/non profit	Tocilizumab	Standard care	RCT	Patients with confirmed COVID-19 (moderate-severe) admitted to multiple centers in the USA	N=28	Low Details	Full description
NCT04331808 CORIMUNO-TOCI-2 Hermine O, Eur Respir J, 2022 Full text Commentary	Public/non profit	Tocilizumab	Standard care	RCT	Patients with suspected or confirmed COVID-19 (severe-critical) admitted to 12 centers in France.	N=97	Some concerns Details	Full description
NCT04412772 ARCHITECTS ARCHITECTS, Unpublished, 2021 Extracted from REACT meta-analysis: Full text	Public/non profit	Tocilizumab	Placebo	RCT	Patients with confirmed COVID-19 (critical) admitted to a single center in the USA.	N=21	Low Details	Full description
NCT04476979 CORIMUNO-TOCIDEX Hermine O, EClinicalMedicine, 2021 Full text Full text Commentary Commentary Commentary	Public/non profit	Tocilizumab + Dexamethasone	Dexamethasone	RCT	Patients with confirmed COVID-19 (moderate) admitted to 25 centers in France and French Guyana.	N=453	Some concerns Details	Full description
NCT02735707 REMAP-CAP Derde L, medRxiv, 2021 Full text Commentary Commentary	Mixed	Tocilizumab Sarilumab Anakinra	Standard care	RCT	Patients with suspected or confirmed COVID-19 (moderate to critical) admitted to 133 centers in 9 countries	N=2253	Some concerns Details	Full description
N/A Hamed D M, J Infect Public Heal, 2021 Full text Commentary	No specific funding	Methylprednisolone +Tocilizumab	Methylprednisolone	RCT	Patients with confirmed COVID-19 (severe) admitted to a single center in Dubai.	N=49	Some concerns Details	Full description
IRCT20081027001411N4 Talaschian M, Research Square, 2021 Full text Commentary Commentary	Public/non profit	Tocilizumab	Standard care	RCT	Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran	N=40	High Details	Full description
Trial NL8504 Rutgers A, PLoS ONE, 2022 Full text Full text Commentary Commentary	Mixed	Tocilizumab	Standard care	RCT	Patients with confirmed COVID-19 (moderate-critical) admitted to 11 centers in the Netherlands.	N=354	Low Details	Full description
NCT04519385 Rashad A, Scientific Reports, 2021 Full text Commentary Commentary	Not reported/unclear	Tocilizumab	Dexamethasone	RCT	Patients with confirmed COVID-19 (severe-critical) admitted to a single center in Egypt	N=149	High Details	Full description
CTRI/2020/05/025369 COVINTOC Soin AS, Lancet Respir Med, 2021 Full text Commentary	Mixed	Tocilizumab	Standard care	RCT	Patients with confirmed COVID-19 (moderate-critical) admitted to 12 centers in India	N=180	Some concerns Details	Full description
NCT04381936, ISRCTN50189673 RECOVERY (TCZ) Horby P, Lancet, 2021 a Full text Commentary Commentary	Public/non profit	Tocilizumab	Standard care	RCT	Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to 131 centers in the UK	N=4116	Some concerns Details	Full description
NCT04403685 TOCIBRAS Veiga VC, BMJ, 2021 Full text Commentary Commentary	Mixed	Tocilizumab	Standard care	RCT	Patients with confirmed COVID-19 (moderate-critical) admitted to 9 centers in Brazil	N=129	Some concerns Details	Full description
NCT02735707 REMAP-CAP Gordon AC, N Engl J Med, 2021 Full text Full text Commentary Commentary	Mixed	Tocilizumab Sarilumab	Standard care	RCT	Patients with confirmed or suspected COVID-19 (severe-critical) admitted to 113 centers in Australia, Ireland, the Netherlands, New Zealand, Saudi Arabia, UK.	N=826	Some concerns Details	Full description
NCT04372186 EMPACTA Salama C, N Engl J Med, 2020 Full text Full text Commentary Commentary	Private	Tocilizumab	Placebo	RCT	Patients with confirmed COVID-19 (mild-severe) admitted to 65 centers in Brazil, Kenya, Mexico, Peru, South Africa, and USA	N=388	Some concerns Details	Full description